Endocannabinoid System's Role in Preventing Tumour Growth | cannabisMD

Endocannabinoid System’s Role in Preventing Tumour Growth

Endocannabinoid System's Role in Preventing Tumour Growth; FASEB

FASEB

Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth

Cannabinoids are a group of chemicals derived from the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and research has shown that it has anti inflammatory properties to heal animals with nervous system disorders. Tetrahydrocannabinol (THC) is another one of these compounds that wields a psychoactive effect in animals. Cannabinoid receptors (CB1 and CB2) are found in the endogenous cannabinoid system and allow cannabinoids to bind and do their job in the body. This paper will look at how the endocannabinoid system regulates tumor growth.

Main Points

  • Endocannabinoids can have anti tumour growth properties
  • Endocannabinoid system a target for therapeutic cannabinoids

Endocannabinoids can have anti tumour growth properties

Since anandamide, an endocannabinoid, is quickly metabolized, this experiment used a metabolically stable cannabinoid. The impact of this cannabinoid was reviewed in a nude mouse model. The cannabinoid induced a massive decrease in tumor size with regard to the treated mice, with no known toxic or effects on the treated animals. This impact was massively induced by the CB1 receptor antagonist, thus indicating the involvement of CB1 receptors in the tumor growth inducing impact. The anti-tumor effect of the cannabinoid was teamed with a strong reduction in the growth of the tumor, which was almost destroyed by the synthetic cannabinoids.

Endocannabinoid system a target for therapeutic cannabinoids

These results suggest that two fundamental parts of the endocannabinoid system, anandamide and the cannabinoid CB1 receptor, hold a possible target site for the advancement of therapeutic drugs mediating tumor growth. Before it was seen that THC decreases the growth of glioma tumors in mice by inhibiting cell death of glioma cancer cells. This impact was stopped by a mixture of CB1 and CB2 cannabinoid receptor antagonists but not by each antagonist alone, giving the job of each cannabinoid receptor subtype in this impact to be understood. This data presents an importance in indicating, for the very first time, that anandamide, which has a lower potential for physical dependence than THC and synthetic cannabinoids, induces tumor growth at non psychotropic doses, the anti-tumor impacts of these drugs can be given through CB1 cannabinoid receptors, and anandamide induces the growth of epithelial tumors, particularly in thyroid cells.

Leave a Reply

Your email address will not be published. Required fields are marked *